BR0315113A - Processo enantioseletivo para a preparação de ambos enantiÈmeros de 10,11-diidro-10-hidróxi-5h-dibenz[b,f]azepina-5-carbox amida e suas formas de cristal - Google Patents

Processo enantioseletivo para a preparação de ambos enantiÈmeros de 10,11-diidro-10-hidróxi-5h-dibenz[b,f]azepina-5-carbox amida e suas formas de cristal

Info

Publication number
BR0315113A
BR0315113A BR0315113-1A BR0315113A BR0315113A BR 0315113 A BR0315113 A BR 0315113A BR 0315113 A BR0315113 A BR 0315113A BR 0315113 A BR0315113 A BR 0315113A
Authority
BR
Brazil
Prior art keywords
dibenz
crystal forms
azepine
hydroxy
dihydro
Prior art date
Application number
BR0315113-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Christian Mathes
Gottfried Sedelmeier
Fritz Blatter
Sabine Pfeffer
Dominique Grimler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0315113A publication Critical patent/BR0315113A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046Ruthenium compounds
    • C07F15/0053Ruthenium compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0315113-1A 2002-10-07 2003-10-06 Processo enantioseletivo para a preparação de ambos enantiÈmeros de 10,11-diidro-10-hidróxi-5h-dibenz[b,f]azepina-5-carbox amida e suas formas de cristal BR0315113A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223224.7A GB0223224D0 (en) 2002-10-07 2002-10-07 Organic compounds
PCT/EP2003/011034 WO2004031155A1 (en) 2002-10-07 2003-10-06 ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF

Publications (1)

Publication Number Publication Date
BR0315113A true BR0315113A (pt) 2005-08-23

Family

ID=9945425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315113-1A BR0315113A (pt) 2002-10-07 2003-10-06 Processo enantioseletivo para a preparação de ambos enantiÈmeros de 10,11-diidro-10-hidróxi-5h-dibenz[b,f]azepina-5-carbox amida e suas formas de cristal

Country Status (20)

Country Link
US (1) US20060142566A1 (https=)
EP (1) EP1551808A1 (https=)
JP (1) JP2006504710A (https=)
KR (1) KR20050071549A (https=)
CN (2) CN1703404A (https=)
AR (1) AR041544A1 (https=)
AU (1) AU2003276055B2 (https=)
BR (1) BR0315113A (https=)
CA (1) CA2501237A1 (https=)
EC (1) ECSP055738A (https=)
GB (1) GB0223224D0 (https=)
HK (1) HK1079790A1 (https=)
MX (1) MXPA05003737A (https=)
NO (1) NO20052244L (https=)
PE (1) PE20040686A1 (https=)
PL (1) PL376379A1 (https=)
RU (1) RU2005114350A (https=)
TW (1) TW200413324A (https=)
WO (1) WO2004031155A1 (https=)
ZA (1) ZA200502561B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
GB0425320D0 (en) 2004-11-17 2004-12-22 Johnson Matthey Plc Diamines
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB2437078A (en) 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
JP5172124B2 (ja) * 2006-09-29 2013-03-27 関東化学株式会社 2位に置換基を有する光学活性キヌクリジノール類の製造方法
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2011045648A2 (en) * 2009-10-12 2011-04-21 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
EP2383261B1 (en) 2010-04-23 2013-09-04 Euticals GmbH Process for the asymmetric hydrogenation of ketones
CN102250005B (zh) * 2010-05-19 2015-04-08 浙江九洲药物科技有限公司 艾利西平的制备方法
US9346760B2 (en) 2011-03-08 2016-05-24 Jubilant Life Sciences Limited Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013167985A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
US20150232426A1 (en) 2012-09-26 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
EP3016961B1 (en) * 2013-07-01 2017-11-15 Boehringer Ingelheim International GmbH Novel ruthenium catalysts and their use for asymmetric reduction of ketones
CN103483257A (zh) * 2013-09-06 2014-01-01 江苏同禾药业有限公司 一种亚氨基芪的合成方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
CN107033079B (zh) * 2016-10-17 2020-07-28 扬子江药业集团北京海燕药业有限公司 醋酸艾司利卡西平的制备方法
CN112679433B (zh) * 2019-10-18 2024-05-24 浙江九洲药业股份有限公司 一种艾利西平的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IL146952A0 (en) * 1999-06-15 2002-08-14 Rhodia Chimie Sa Sulphonylamides and carboxamides and their use in asymmmetical catalysis
JP2004526706A (ja) * 2001-02-12 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド オクスカルバゼピンの新しい結晶形態及びそれらの調製方法

Also Published As

Publication number Publication date
MXPA05003737A (es) 2005-06-17
CN1703404A (zh) 2005-11-30
TW200413324A (en) 2004-08-01
WO2004031155A1 (en) 2004-04-15
AU2003276055B2 (en) 2008-01-03
AU2003276055A1 (en) 2004-04-23
CN101062932A (zh) 2007-10-31
US20060142566A1 (en) 2006-06-29
KR20050071549A (ko) 2005-07-07
ECSP055738A (es) 2005-07-06
RU2005114350A (ru) 2006-01-20
PE20040686A1 (es) 2004-10-29
PL376379A1 (en) 2005-12-27
NO20052244L (no) 2005-07-07
HK1079790A1 (zh) 2006-04-13
GB0223224D0 (en) 2002-11-13
CA2501237A1 (en) 2004-04-15
AR041544A1 (es) 2005-05-18
JP2006504710A (ja) 2006-02-09
ZA200502561B (en) 2006-02-22
NO20052244D0 (no) 2005-05-06
EP1551808A1 (en) 2005-07-13

Similar Documents

Publication Publication Date Title
BR0315113A (pt) Processo enantioseletivo para a preparação de ambos enantiÈmeros de 10,11-diidro-10-hidróxi-5h-dibenz[b,f]azepina-5-carbox amida e suas formas de cristal
BR0110331A (pt) Substâncias que mimetizam beta que têm uma atividade de longa duração, processos para prepará-las e o uso das mesmas como medicamentos
MX2009012608A (es) Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
HUP9902056A2 (hu) Fuzionált 1,2,4-tiadiazin- és fuzionált 1,4-tiazinszármazékok, azok előállítása és alkalmazása
PT93825B (pt) Processo para a preparacao de derivados da piperazina
BR0015544A (pt) Polimorfo estável de cloridrato de n-( 3-etinilfenilamino )-6,7-bis( 2-metoxietóxi)-4-quinazolinamina, métodos de produção, e usos farmacêuticos dos mesmos
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
MX2011002705A (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
HUP0300846A2 (hu) Imidazopirimidin- és triazolopirimidin-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények
YU40300A (sh) Aril fuzirana azapoliciklična jedinjenja
SE8503613D0 (sv) 5h-2,3-benzodiazepine derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
DE69510928D1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
DE69406594D1 (de) Hydrierung von aromatischen Aminen zur Herstellung der entsprechenden ringhydrierten Verbindungen
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
PT81893A (de) Verfahren zur herstellung von labdan-derivaten und ihre verwendung als arzneimittel
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BR0314796A (pt) Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia
HUP0302616A2 (hu) Triptaminszármazékok és analóg vegyületek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DE69832302D1 (de) Antikonvulsive und zns-aktive bis-fluoralkylamide
BR0107922A (pt) Derivados de dibenzo[b,f]azepina e sua preparação
DE69815306D1 (de) Valnoctamid-stereoisomere, eine methode zu ihrer herstellung und abtrennung und ihre anwendungen
ATE334680T1 (de) 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
BRPI0410613A (pt) preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano
DE69808922D1 (de) Thiazolobenzoheterocyclen, ihre herstellung und diese enthaltende phatrmazeutische zubereitungen
BR9911615A (pt) 2-aminopiridinas contendo substituintes de anel fundido como inibidores de sintase de óxido nìtrico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.